Parabilis Medicines (PBLS) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Xenon Pharmaceuticals is the larger company by market cap ($3.50 billion vs $3.47 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBLS | XENE |
|---|---|---|
| Share price | $28.09 | $36.16 |
| Market cap | $3.47B | $3.50B |
| 1-day change | -2.53% | -0.69% |
| YTD return | — | -19.32% |
| 1-year return | — | -7.87% |
| 5-year return | — | +7.43% |
| EPS (TTM) | $-9.51 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $7.50M |
| Net income (latest FY) | — | $-345.91M |
| Operating margin | — | -4974.27% |
| Net margin | — | -4612.13% |
| 52-week high | $42.49 | $72.66 |
| 52-week low | $24.51 | $35.06 |
| Distance from 52-week high | -33.89% | -50.23% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +48.63% | +102.90% |
| Average volume | 690.91K | 1.43M |
| Shares outstanding | 121.95M | 96.84M |
| Employees | 145 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
PBLS vs XENE FAQ
Which is bigger, Parabilis Medicines or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.50B compared with $3.47B for Parabilis Medicines (PBLS).
Are Parabilis Medicines and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.